Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 152 No. 0304 (2022)

Has the profile of heart transplantation recipients changed within the last three decades?  : An analysis from the Lausanne Heart Transplantation Centre

  • Anouck  Zurbuchen
  • Piergiorgio Tozzi
  • Julien Regamey
  • Tamila Abdurashidova
  • Philippe Meyer
  • Karl Lefol
  • Manuel Pascual
  • Patrick Yerly
  • Vincent Aubert
  • Stefania Aur
  • Valentina Rancati
  • Carlo Marcucci
  • Marco Rusca
  • Sam Rotman
  • Rene Pretre
  • Matthias Kirsch
  • Roger Hullin
Cite this as:
Swiss Med Wkly. 2022;152:w30108



BACKGROUND: Heart transplantation remains the most durable treatment for patients with end-stage heart failure refractory to medical treatment. Central elements of the listing criteria for heart transplantation have remained largely unchanged in the last three decades whereas treatment of heart failure has significantly increased survival and reduced disease-related symptoms. It remains unknown whether the improvement of heart failure therapy changed the profile of heart transplantation candidates or affected post-transplant survival. 

METHODS: The study investigated a total of 323 heart transplant recipients of the Lausanne University Hospital with 328 transplant operations between 1987 and 2018. Patients were separated into three groups on the basis of availability of heart failure therapy: period 1 (1987–1998; n = 115) when renin-angiotensin system blockade and diuretic treatment were available; period 2 (1999–2010; n = 106) marked by the addition of beta-blocker and mineralocorticoid receptor antagonist treatment in severe heart failure, and the establishment of cardiac defibrillator and resynchronisation therapy; period 3 (2011–2018; n = 107) characterised by the increasing use of ventricular assist devices for bridge to transplantation.

RESULTS: The patient characteristics age (all: 53.4 years), male sex (all: 79%) and body mass index (all: 24.5 kg/m2) did not differ between periods. History of arterial hypertension was less prevalent in period 2 (period 1 vs 2 vs 3: 44 vs 28 vs 43%, p = 0.04) whereas other cardiovascular risk factors were equally distributed. Left ventricular ejection fraction, VO2max, and pulmonary vascular resistance were not different between the three periods. The prevalence of ischaemic cardiomyopathy was higher in periods 1 and 3; dilated non-ischaemic cardiomyopathy was more frequent in period 2. Post-transplant 1-year survival was highest in period 3 (1 vs 2 vs 3: 87.2 ± 3.2% vs 70.8 ± 4.4% vs 93.0 ± 2.6%, p always ≤0.02), and the Kaplan-Meier estimates of survivors of the  first year post-transplant were not different between the three periods. In descriptive analysis, early mortality was not associated with acknowledged pretransplant predictors of post-transplant mortality. 

CONCLUSION: Availability of different medical heart failure treatments did not result in greatly different pretransplant characteristics of heart transplantation recipients across the three periods. This suggests that the maintained central criteria of listing for heart transplantation still identify end-stage heart failure patients with a similar profile. This finding can explain the unchanged overall mortality on condition of 1-year survival across the three periods, since pretransplant characteristics are relevant for long-term survival after heart transplantation.


  1. Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967 Dec;41(48):1271–4.
  2. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun;316(23):1429–35.
  3. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al.; ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999 Dec;100(23):2312–8.
  4. CIBIS II investigators and committees. The cardiac insufficiency bisoprolol study II (CIBIS II): a randomised trial. Lancet. 1999 Jan;353(9146):9–13.
  5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999 Sep;341(10):709–17.
  6. Cohn JN, Tognoni G ; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 Dec;345(23):1667–75.
  7. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003 Sep;362(9386):772–6.
  8. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002 Mar;346(12):877–83.
  9. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr;352(15):1539–49.
  10. Khush KK, Cherikh WS, Chambers DC, Harhay MO, Hayes D Jr, Hsich E, et al.; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019 Oct;38(10):1056–66.
  11. Mehra MR, Uriel N, Naka Y, Cleveland JC Jr, Yuzefpolskaya M, Salerno CT, et al.; MOMENTUM 3 Investigators. A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. N Engl J Med. 2019 Apr;380(17):1618–27.
  12. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991 Mar;83(3):778–86.
  13. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: international Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant. 2006 Sep;25(9):1024–42. j.healun.2006.06.008
  14. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al.; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1–23.
  15. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov;310(20):2191–4.
  16. Dec GW, Narula J, Ballester M, Carrio I. Cardiac allograft rejection. New York: Springer Science&Business Media, LCC; 2001. 434 p.
  17. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005 Nov;24(11):1710–20.
  18. McAllister HA Jr, Schnee MJ, Radovancević B, Frazier OH. A system for grading cardiac allograft rejection. Tex Heart Inst J. 1986 Mar;13(1):1–3.
  19. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al.; American Heart Association; Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; Council on Epidemiology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006 Apr;113(14):1807–16.
  20. Nanna MG, Hajduk AM, Krumholz HM, Murphy TE, Dreyer RP, Alexander KP, et al. Sex-based differences in presentation, treatment, and complications among older adults hospitalized for acute myocardial infarction: the SILVER-AMI study. Circ Cardiovasc Qual Outcomes. 2019 Oct;12(10):e005691.
  21. Stehlik J, Edwards LB, Kucheryavaya AY, Aurora P, Christie JD, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report—2010. J Heart Lung Transplant. 2010 Oct;29(10):1089–103.
  22. Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al.; International Society for Heart and Lung Transplantation. The registry of the International Society of Heart and Lung Transplantation : Thirty-third adult heart transplantation report - 2016; Focus theme: primary diagnostics for transplant. J Heart Lung Transplant. 2016 Oct;35(10):1158–69.
  23. Taegtmeyer AB, Rogers P, Breen JB, Barton PJ, Banner NR, Yacoub MH. The effects of pre- and post-transplant anemia on 1-year survival after cardiac transplantation. J Heart Lung Transplant. 2008 Apr;27(4):394–9.
  24. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013 Apr;165(4):575–582.e3.
  25. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011 Nov;17(11):899–906.
  26. Russo MJ, Chen JM, Sorabella RA, Martens TP, Garrido M, Davies RR, et al. The effect of ischemic time on survival after heart transplantation varies by donor age: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg. 2007 Feb;133(2):554–9.
  27. Lund LH, Khush KK, Cherikh WS, Goldfarb S, Kucheryavaya AY, Levvey BJ, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant. 2017 Oct;36(10):1037–46.
  28. Weiss J, Beyeler F, Immer FF, Swisstransplant H ; Swisstransplant Heart Working Group Stah. Heart allocation and transplantation in Switzerland since the introduction of the Swiss Organ Allocation System (SOAS). Swiss Med Wkly. 2014 Nov;144:w14057.
  29. Truby LK, Farr MA, Garan AR, Givens R, Restaino SW, Latif F, et al. Impact of Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices on Posttransplantation Mortality. Circulation. 2019 Aug;140(6):459–69.
  30. Nowacka A, Hullin R, Tozzi P, Barras N, Regamey J, Yerly P, et al. Short-term single-centre experience with the HeartMate 3 left ventricular assist device for advanced heart failure. Eur J Cardiothorac Surg. 2020 Sep;58(3):511–8.
  31. Tozzi P, Banfi C, Ahmadov K, Hullin R, Meyer P, Giraud R, et al. HeartMate 3 in Lowest INTERMACS Profile Cohort: the Swiss Experience. ASAIO J. 2017 Nov/Dec;63(6):752–8.
  32. Tozzi P, Nowacka A, Hullin R, Yerly P, Kirsch M. The role of Heart Failure Team in managing Mechanical Circulatory Support in a Swiss low-volume institution. Heart Surg Forum. 2018 Jun;21(4):E257–62.
  33. Söderlund C, Öhman J, Nilsson J, Higgins T, Kornhall B, Johansson L, et al. Acute cellular rejection the first year after heart transplantation and its impact on survival: a single-centre retrospective study at Skåne University Hospital in Lund 1988-2010. Transpl Int. 2014 May;27(5):482–92.
  34. Schmidhauser M, Regamey J, Pilon N, Pascual M, Rotman S, Banfi C, et al. The impact of multidisciplinary care on early morbidity and mortality after heart transplantation. Interact Cardiovasc Thorac Surg. 2017 Sep;25(3):384–90.
  35. Seferović PM, Piepoli MF, Lopatin Y, Jankowska E, Polovina M, Anguita-Sanchez M, et al.; Heart Failure Association Board of the European Society of Cardiology. Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. Eur J Heart Fail. 2020 May;22(5):763–74.
  36. Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al.; PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1–11.
  37. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients J Heart Lung Transplant 2010; 29 8):914-956. doi:

Most read articles by the same author(s)

<< < 1 2